STAAR Surgical Company
STAA · NASDAQ
Company research
STAAR Surgical Company (NASDAQ: STAA) is a Lake Forest, California-based medical device company that has been dedicated solely to ophthalmic surgery since its founding in 1982, positioning itself as the global leader in implantable phakic intraocular lenses (IOLs). The company designs, develops, manufactures, and markets its proprietary Implantable Collamer® Lenses (ICLs), most notably the EVO ICL™ product line, which are made from its unique biocompatible Collamer material and used to correct myopia, hyperopia, and astigmatism without removing corneal tissue or the eye's natural lens. Having surpassed 4 million ICLs sold across more than 85 countries, STAAR distributes its products through a combination of direct sales forces and independent distributors, serving ophthalmologists, surgical centers, hospitals, and healthcare facilities worldwide. With approximately 1,157 full-time employees and a market capitalization of approximately $1.36 billion, the company also offers preloaded silicone intraocular lenses and ancillary delivery systems for cataract surgery, and operates manufacturing and packaging facilities in California and Nidau, Switzerland.
Research reports
Flash frames STAAR as a niche monopolist in phakic intraocular lenses whose 2025 revenue decline and China inventory reset, along with a failed Alcon deal and one-time restructuring and merger costs, have temporarily depressed earnings despite maintaining roughly 76% gross margins and a sizable net cash position. The report presents a governance-driven turnaround with shareholder-aligned leadership and a 5-year scenario analysis leading to a probability-weighted target price of about 44.50 per share, while flagging key risks including China concentration, macro and geopolitical shocks, competitive pressure from laser platforms and new phakic lens entrants, and execution risk under interim co-CEOs.
HDIN Research · March 10, 2026Ophthalmic Sector 2025: Unpacking STAAR Surgical’s Structural Headwinds and the Strategic Moats of Industry GiantsThis HDIN Research sector piece highlights STAAR’s 23.7% revenue drop in 2025, roughly 80.4 million net loss, about 40 million negative free cash flow, and SG&A running at approximately 114.5% of revenue, arguing that a single‑product, China‑heavy model leaves the company structurally exposed versus diversified incumbents like Alcon and Carl Zeiss Meditec. It concludes that valuation premia in ophthalmic devices are migrating toward platform-based “one‑stop shop” players with recurring consumables cash flow, and that STAAR must urgently fix channel inventory in China, reduce working-capital strain, and accelerate next‑generation presbyopia products if it is to regain investor confidence.
StockStory · December 10, 2025STAAR Surgical (STAA) Research ReportStockStory’s research page characterizes STAAR as a small, scale-disadvantaged medical device company with decent five‑year revenue CAGR but recent double‑digit annualized revenue declines, weak historical adjusted operating margins, deteriorating ROIC, and poor cash flow conversion relative to its risk profile. It notes that shares trade at an extremely expensive forward P/E multiple (around 50× at the time) despite these fundamentals, and explicitly states they would not buy the stock and instead prefer other names, even though sell‑side models forecast a sharp revenue and EPS recovery over the next 12 months.